Silo Pharma (SILO) Fundamentals 2026 — Revenue Analysis | SniperIQ
Silo Pharma (SILO) is a US-listed Healthcare company in Biotechnology with a market capitalization of $4M, trading at $4.55 on the NASDAQ. This SniperIQ fundamentals page covers Silo Pharma's valuation, profitability (net margin -6717.4%), revenue ($72,102 in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Silo Pharma's market cap?
Silo Pharma (SILO) has a market capitalization of approximately $4M, trading at $4.55 on the NASDAQ. Market cap moves with the live share price.
What is Silo Pharma's P/E ratio?
Silo Pharma's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Silo Pharma?
Silo Pharma runs a net profit margin of -6717.4%, a gross margin of -328.7%, and an operating margin of -6631.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Silo Pharma generate?
Silo Pharma reported revenue of $72,102 for fiscal year 2025, with net income of -$4M and earnings per share (EPS) of -7.5. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Silo Pharma pay a dividend?
Silo Pharma does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Silo Pharma financially healthy?
Silo Pharma carries a debt-to-equity ratio of 0.00x and a current ratio of 9.65x, with a market beta of 0.75. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Silo Pharma a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Silo Pharma (SILO) the key facts are: market cap $4M, revenue $72,102, 52-week range 3.315-15.15. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Silo Pharma's full fundamentals live
Get Silo Pharma's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.